Search research articles
Contact Us
Filters
Showing results (491-500 of 659) with videos related to
Page
of 66
Sort By:
Leukemia & Lymphoma
|
September 3, 2021
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine
Sangeetha Venugopal, Abhishek Maiti, Courtney D DiNardo, et al.
Acta Haematologica
|
April 15, 2020
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Abhishek Maiti, Miguel J Franquiz, Farhad Ravandi, et al.
American Journal of Hematology
|
May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1
Nicholas J Short, Elias Jabbour, Walid Macaron, et al.
Blood Advances
|
December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
Nicholas J Short, Hind Rafei, Naval Daver, et al.
Blood
|
August 25, 2017
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment
Ghayas C Issa, Hagop M Kantarjian, Graciela Nogueras Gonzalez, et al.
Cancer
|
April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
Elias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Blood Advances
|
November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
Nicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
American Journal of Hematology
|
January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results
Hagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Leukemia & Lymphoma
|
October 31, 2025
Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia
Roberta S Azevedo, Julie Braish, Georgina Gener-Ricos, et al.
Leukemia & Lymphoma
|
March 31, 2025
Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions
Eitan Kugler, Enes Dasdemir, Alex Bataller, et al.
Page
of 66
Search research articles
Search
Showing results (491-500 of 659) with videos related to
Sort By:
Page
of 66
Leukemia & Lymphoma
|
September 3, 2021
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine
Sangeetha Venugopal, Abhishek Maiti, Courtney D DiNardo, et al.
Acta Haematologica
|
April 15, 2020
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Abhishek Maiti, Miguel J Franquiz, Farhad Ravandi, et al.
American Journal of Hematology
|
May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1
Nicholas J Short, Elias Jabbour, Walid Macaron, et al.
Blood Advances
|
December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
Nicholas J Short, Hind Rafei, Naval Daver, et al.
Blood
|
August 25, 2017
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment
Ghayas C Issa, Hagop M Kantarjian, Graciela Nogueras Gonzalez, et al.
Cancer
|
April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
Elias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Blood Advances
|
November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
Nicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
American Journal of Hematology
|
January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results
Hagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Leukemia & Lymphoma
|
October 31, 2025
Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia
Roberta S Azevedo, Julie Braish, Georgina Gener-Ricos, et al.
Leukemia & Lymphoma
|
March 31, 2025
Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions
Eitan Kugler, Enes Dasdemir, Alex Bataller, et al.
Page
of 66